PROBLEM OF SUPERINFECTIONS: WORLD THREAT OF DEATH OR POSSIBILITY OF ITS GLOBAL OVERCOMING?

Abstract

According to WHO, in 2017, 10.4 million of patients fell ill with tuberculosis, 47 % of patients became infected with multi drug resistance for antimycobacterial drugs, and 1.7 mln. of them died. Each year, they record up to 700 thousand deaths from infectious diseases in the field of Pulmonology: COPD, bronchial asthma, atypical pneumonia, and interstitial lung diseases. Generalized septic infections with suppuration, corona viruses cause mutations of microorganisms to the antibacterial drugs and form drug resistance.

The aim of the study – to improve early diagnosis of drug-resistant superbacteria and interrupt the ways of its formation through molecular technological methods.

An overview of the data showed the need for improvement in medical institutions of early diagnosis of superinfections, which will warn the formation of extended resistance of microorganisms to antibacterial drugs. The high rate of formation of resistance of bacteria now have ahead of the introduction of new antimicrobial agents, which poses a threat to an ageing population of the planet. Due to the resistance of microorganisms, mixed specific and non-specific flora to the main drugs worldwide, there is the emergence of global disease with superinfection, which is caused by “superbacteria – nightmarebacteria – Superbug”. Due to the low level of modern molecular diagnostics this level of “superinfections” is hidden and the quantity is significantly understated. In the absence of effective global steps to reduce the rate of resistance to microorganisms, the planet’s population by 2050 may decrease by 10 million people per year, due to reactivation of atypical pneumonia, secondary tuberculosis (TB), expansion on the planet of total resistant tuberculosis (XXDR).

Conclusions. The introduction of modern molecular-genetic technologies will allow accurately establishing the etiology process, to conduct the identification of mycobacteria and microorganisms and to determine the phenotymetric and genotytypical sensitivity of bacteria to Antimycobacterial drugs. Such diagnostics will promote effective treatment of patients who are already infected with persistent strains of bacteria.